MACS® GMP PepTivator® PRAME

The MACS GMP PepTivator PRAME is a is a peptide pool that consists mainly of 15-mer peptides. It has been developed for efficient in vitro stimulation and subsequent isolation of PRAME-specific CD4+ and CD8+ T cells.

Related products for MACS® GMP PepTivator® PRAME

Specifications for MACS® GMP PepTivator® PRAME
Overview

The MACS GMP PepTivator PRAME is a is a peptide pool that consists mainly of 15-mer peptides. It has been developed for efficient in vitro stimulation and subsequent isolation of PRAME-specific CD4+ and CD8+ T cells.

Detailed product information
Background information

PepTivator® PRAME is a pool of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap, covering the complete sequence of the preferentially expressed antigen of melanoma (PRAME) (UniProt ID: P78395).

In vitro stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.1,2

Applications

The MACS GMP PepTivator PRAME is used for in vitro stimulation of PRAME-specific effector and memory T cells.

This product has not yet been tested in conjunction with the CliniMACS Cytokine Capture System (IFN-gamma).

Quality statement

MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.

Disclaimer

MACS GMP Products are for ex vivo cell processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative.

Resources for MACS® GMP PepTivator® PRAME
Certificates

Enter the lot number from your product label to access its Product Quality Certificated (PQC).

Get certificate

Citations for MACS® GMP PepTivator® PRAME
Publications
  1. Gérard, C. et al. (2015) A comprehensive preclinical model evaluating the recombinant PRAME antigen combined with the AS15 immunostimulant to fight against PRAME-expressing tumors. J Immunother 38 (8): 311-320
  2. Pollack, S. M. et al. (2012) NYESO-1/LAGE-1s and PRAME are targets for antigen-specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One 7 (2): e32165
  3. Spel, L. et al. (2015) Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget. 6 (34): 35770-35781

You have previously chosen International as your location.
What do you want to do?